Key Findings and Conclusions from MARIPOSA-2 Trial

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.